JP2024539476A5 - - Google Patents
Info
- Publication number
- JP2024539476A5 JP2024539476A5 JP2024530487A JP2024530487A JP2024539476A5 JP 2024539476 A5 JP2024539476 A5 JP 2024539476A5 JP 2024530487 A JP2024530487 A JP 2024530487A JP 2024530487 A JP2024530487 A JP 2024530487A JP 2024539476 A5 JP2024539476 A5 JP 2024539476A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- flumonertinib
- pharmaceutically acceptable
- acceptable salt
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111404293.6A CN116159062A (zh) | 2021-11-24 | 2021-11-24 | 药物组合物及其用途 |
| CN202111404293.6 | 2021-11-24 | ||
| PCT/CN2022/133171 WO2023093663A1 (en) | 2021-11-24 | 2022-11-21 | Pharmaceutical composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539476A JP2024539476A (ja) | 2024-10-28 |
| JP2024539476A5 true JP2024539476A5 (https=) | 2025-12-02 |
Family
ID=86416859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024530487A Pending JP2024539476A (ja) | 2021-11-24 | 2022-11-21 | 医薬組成物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250017927A1 (https=) |
| EP (1) | EP4436580A4 (https=) |
| JP (1) | JP2024539476A (https=) |
| KR (1) | KR20240124921A (https=) |
| CN (2) | CN116159062A (https=) |
| AU (1) | AU2022397653A1 (https=) |
| CA (1) | CA3238480A1 (https=) |
| IL (1) | IL312874A (https=) |
| MX (1) | MX2024006168A (https=) |
| WO (1) | WO2023093663A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
| CN116854694B (zh) * | 2023-07-04 | 2024-07-09 | 北京浦润奥生物科技有限责任公司 | [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105315259B (zh) * | 2014-07-29 | 2018-03-09 | 上海艾力斯医药科技有限公司 | 吡啶胺基嘧啶衍生物、其制备方法及应用 |
| MX2022007969A (es) * | 2019-12-23 | 2022-12-13 | Blueprint Medicines Corp | Inhibidores de egfr. |
| WO2023035223A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海艾力斯医药科技股份有限公司 | 药物组合物及其用途 |
| WO2024059962A1 (en) * | 2022-09-19 | 2024-03-28 | Shanghai Allist Pharmaceuticals Co., Ltd. | Pharmaceutical composition and use thereof |
-
2021
- 2021-11-24 CN CN202111404293.6A patent/CN116159062A/zh active Pending
-
2022
- 2022-11-21 AU AU2022397653A patent/AU2022397653A1/en active Pending
- 2022-11-21 WO PCT/CN2022/133171 patent/WO2023093663A1/en not_active Ceased
- 2022-11-21 CA CA3238480A patent/CA3238480A1/en active Pending
- 2022-11-21 US US18/712,357 patent/US20250017927A1/en active Pending
- 2022-11-21 KR KR1020247020083A patent/KR20240124921A/ko active Pending
- 2022-11-21 IL IL312874A patent/IL312874A/en unknown
- 2022-11-21 CN CN202280078292.3A patent/CN118678958A/zh active Pending
- 2022-11-21 MX MX2024006168A patent/MX2024006168A/es unknown
- 2022-11-21 JP JP2024530487A patent/JP2024539476A/ja active Pending
- 2022-11-21 EP EP22897746.8A patent/EP4436580A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024533423A5 (https=) | ||
| CA2856646C (en) | Combination treatment of cancer | |
| JP2024539476A5 (https=) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| CN112638378A (zh) | 用于根除幽门螺杆菌的组合物 | |
| EP4342475A1 (en) | Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient | |
| WO2023100070A1 (en) | Cdk4 inhibitor for the treatment of cancer | |
| TWI344367B (en) | Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| TW202541803A (zh) | 含有三氟甲基的化合物在治療血液腫瘤中的應用 | |
| EP4087572A1 (en) | Combination therapy for treating cancer | |
| CN115135326B (zh) | 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途 | |
| JP2022506019A (ja) | 高用量の放出調節フペルジン製剤の使用 | |
| CN118338901A (zh) | 用于治疗癌症的cdk4抑制剂 | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| JP7536987B2 (ja) | 脈管奇形用医薬組成物及び脈管奇形の治療方法 | |
| HK1205951A1 (en) | Use of 7-t-butoxyiminomethylcamptothecin for the prepartion of a medicament for the treatment of uterine neoplasms | |
| JP6937065B1 (ja) | 間質性肺炎の治療剤 | |
| WO2026021478A1 (zh) | Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法 | |
| WO2026021460A1 (zh) | 治疗前列腺癌的方法 | |
| WO2026092748A1 (zh) | 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌 | |
| TWI922738B (zh) | 化合物或其藥劑學上可接受的鹽用於製造實性瘤治療用醫藥組成物之用途 | |
| AU2012276476A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| TWI735658B (zh) | 用於減少代謝症候群之組合物及其應用 |